Drug intelligence / Profile preview

Niaosuanqing

Development stage: Unknown
Administration: Oral

Overview

Niaosuanqing (尿酸清颗粒) is a traditional Chinese medicine (TCM) formulation used primarily for the management of hyperuricemia and gout. It is composed of multiple herbal ingredients, commonly including plant extracts such as Smilax glabra (土茯苓), Plantago asiatica (车前草), and other herbs traditionally believed to promote uric acid excretion and reduce inflammation. The mechanism of action is thought to involve inhibition of xanthine oxidase activity, reduction in uric acid synthesis, promotion of renal uric acid excretion, and anti-inflammatory effects. Niaosuanqing is widely used in China as an adjunct or alternative therapy for patients with elevated serum uric acid levels or gouty arthritis.

Brand names: Niaosuanqing尿酸清颗粒
Other names: 尿酸清颗粒

Targets

GLUT9 (Glucose transporter type 9)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on Niaosuanqing.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niaosuanqing.

Explore the full profile